Stanley Erck, Novavax CEO (Andrew Harnik, AP Images)

Covid-19 roundup: SAB's an­ti­body treat­ments move to PhI­II; Af­ter long jour­ney, No­vavax sub­mits vac­cine to WHO for re­view

A day af­ter the com­pa­ny lands an­oth­er $60.5 mil­lion to help ad­vance an an­ti­body Covid-19 treat­ment, SAB Bio­ther­a­peu­tics has an­nounced a pos­i­tive re­view from the Da­ta Mon­i­tor­ing Safe­ty Board, and will move in­to Phase III tri­als.

Both of the dos­es test­ed in a Phase II tri­al met the pre-tri­al ef­fi­ca­cy goals, the com­pa­ny says, though tri­al re­sults have not yet been post­ed to the clin­i­cal­tri­ web­site.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.